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Figure 3: Comparison of Th2+Th17 cTFH (Left) and (Th2+Th17)/Th1 cTFH ratio (Right) in patients without cGVHD (N¼38) and with cGVHD (N¼33).
Figure 1. (Left) Recovery of tTFH and CD4+ T-cells/mL) after HSCT. (Right) Frequencies of cTFH in the CD4+ T-cell gate beginning 2 months after HSCT. Number of
patients analyzed for each time point is indicated below the graph. Dashed lines represent the median values from 11 Healthy Donors (90% CI plotted in light red and
light grey for the respective population).
Figure 2. Assessment of B-tell helper function in cTFH subsets. cTFH (CD4+CD45RA-CXCR5+) and non-cTFH (CD4+CD45RA-CXCR5-) T cell subsets were puriﬁed by
ﬂow cytometric cell sorting. IgG (left) and IgM (Right) production was measured in supernatants? after 12-day co-culture of puriﬁed T-cell subsets with naive B-cells
stimulated with Staphylococcal Enterotoxin B.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S147eS170 S165cGVHD patients, we observed a selective decrease of the Th1
compartment in the cTFH subset (16.2% and 10.9% for No vs.
cGVHD, p¼0.034), and relative increase of both Th2 and Th17
cTFH (Th2+Th17¼ 71.15 and 78.1% respectively, p¼0.07)
leading to a greater (Th2+Th17)/Th1 ratio (p¼0.044) (Figure
3). We did not ﬁnd any differences in cTFH subsets when
comparing Mild vs. Moderate and Severe cGVHD. To further
characterize cTFH, we analyzed BCL-2 and CD95 apoptosis
pathways. Th2 and Th17 cTFH subsets appeared to express
lower levels of CD95 and higher levels of BCL-2 compared to
Th1 cTFH.
Increased representation of Th2 and Th17 cTFH subsets
that are relatively resistant to apoptosis may be amechanismthat promotes B-cell deregulation and pathologic antibody
production in patients with cGVHD. Targeting Th2/Th17 cTFH
or TFH-B cell interactions may provide novel therapies in
patients with cGVHD.204
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CMV reactivation has been associated with increased non-
relapsemortality (NRM)and improvedearly relapse incidence
(RI) post HLA matched allogeneic hematopoietic stem cell
transplant (HSCT), however, it’s effect has been less exten-
sively studied inTcell repletehaploidentical (HI)HSCT. In the2
step approach to HI HSCT developed at our institution, a large
ﬁxeddose of Tcells (2 x 108) is administered after conditioning
( Step 1), followed 2 days later bycyclophosphamide (CY) for T
cell tolerization. In Step 2, a CD34-selected stemcell product is
infused 1 day after completing CY. A signiﬁcant increase in T
cell numbers, especially in CD3/8 counts, was associated with
CMVreactivation inmanypatients treatedwith this approach.
We hypothesized that a CMV-associated increase in CD3/8
counts would impact HSCT outcomes.
A retrospective outcomes analysis (OS, NRM and RI) using
multivariable proportional hazards regression was per-
formed on all patients enrolled on a 2 step clinical trial since
2006, whowere alive and disease free at D90 (n¼106). High v
low CD3/8 count at D90, a history of GVHD treated with
steroids and CMV reactivation (deﬁned by > 100 copies/ml
by PCR) both by D90, were the factors of interest. Known
predictors of outcomes including disease at HSCT and he-
matopoietic comorbidity index (HCT CI) were included in the
analysis. The median CD3/8 count for the group, 125 cells/ul,
was used to differentiate CD8H v CD8L levels.
43% patients reactivated CMV prior to D90. The median
CD3/8 count for CMV-R (reactivators) v CMV-NR (non-
reactivators) was 308.4 v 53.7 cells/ul (p<0.0001). For the
whole group, CD8H had a signiﬁcant protective effect for OS
and NRM. CMV reactivation, disease at HSCT and higher HCT
CI score had a signiﬁcant negative impact. Table 1. No var-
iables were signiﬁcantly associated with RI. In a subset
analysis, patients with acute GVHD/CD8H had superior OS
in both CMV-R and CMV-NR groups. CMV-NR patients with
CD8L/no acute GVHD had the poorest OS. Fig 1. CMV-R
patients with CD8L had equally poor OS with or without
acute GVHD. Fig 2.
Higher CD3/8 counts were signiﬁcantly associated with
improved OS and lower NRM in all patients irrespective of
CMV reactivation. Higher CD3/8 counts in CMV-R patients
may mitigate the effects of CMV reactivation while preser-
ving the beneﬁcial effects of GVHD on OS, a ﬁnding that re-
quires further investigation. Prospective analyses of CD3/8
and CD3/4 numbers and strategies to increase them such as
early withdrawal of immunosuppression are warranted.Table 1
Multivariable model for OS
Variable Comparison Hazard Ratio (95% CI) p-value
CMV D90 R v NR 3.28 (1.19,9.05) 0.022
CD8 D90 CD8L v CD8H 3.87 (1.39,10.8) 0.0096
GVHD/Steroid D90 Y v N 0.71 (0.32,1.57) 0.40
Dz at HSCT N v Y 0.27 (0.11,0.65) 0.0036
HCTCI 1 unit increase 1.43 (1.08,1.90) 0.013
Age 1 year increase 0.99 (0.97,1.02) 0.60
Conditioning Myelo v RIC 1.36 (0.63,2.94) 0.44205
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Graft failure (GF) after hematopoietic cell transplant (HCT)
occurs in 5-30[DW1] % of patients. GF can be accompanied by
neutropenia (NGF)or can resultwithadequateneutrophils, but
loss ofdonor chimerism (non-neutropenic graft failure,NNGF).
We analyzed the outcomes of 61 patients (pediatric and adult)
treated with a second HCT for GF at the University of Minne-
sota; 27withNGFand34withNNGF. The cumulative incidence
of neutrophil engraftment at 42days after secondHCTwas88%
forNNGF, and 68% forNGF (p¼0.03). The incidence of grade III-
IV acute graft versus host disease (GVHD) was 15% (95% con-
ﬁdence interval (CI), 2 e 28%) and 6% (95% CI, 2 - 17%) for NGF
and NNGF, respectively (p ¼ 0.17). From the 2ndHCT, 1-year
